MTCH2 and obesity due to melanocortin 4 receptor deficiency: Importantly from a therapeutic perspective, pharmacological or gene‐based interventions aimed at modulating MTCH2 activity could offer promising strategies for treating metabolic disorders such as obesity and insulin resistance.